TuHURA Biosciences, Inc./NV (HURA) · Nov 18, 2026 · New debt
$1.3M borrowing — $650,000 drawn November 12 and November 18; $1.3M aggregate
TuHURA’s latest debt filing discloses $1.3 million of new borrowing. It supports near-term clinical operations but underscores continued reliance on financing.
TuHURA is a cash-burning Phase 3 immuno-oncology company advancing IFx-2.0 in Merkel cell carcinoma, TBS-2025 toward Phase 1b/2 development, and early ADC programs. Its latest quarterly filing showed $1.9 million of cash at September 30, 2026, $18.1 million of operating cash burn for the first nine months, and reliance on the Parkview facility to fund operations into 2028.
The filing adds real near-term liquidity, not a new financing framework. TuHURA borrowed $650,000 on each of November 12 and November 18, for $1.3 million in total, and plans to use the money for general corporate purposes.
| Loan detail | Figure | Comparison |
|---|---|---|
| New borrowing (Item 2.03) | $1.3M | — |
| Borrowing per draw (Item 2.03) | $650,000 | — |
| Maximum facility availability (Item 2.03) | $50M | — |
| Facility maturity (Item 2.03) | April 21, 2031 | — |
The positive is funding continuity; the negative is continued dependence on debt. The $50 million revolving facility was already announced in April and was designed for monthly drawdowns supporting clinical development and operations, so the direction of this event was expected rather than surprising. The new information is the amount actually drawn. The cash helps keep the pipeline moving, but it does not improve operating performance or reduce the company’s underlying financing need; it adds to obligations for a business that has been consuming cash at a substantial rate.
Bottom line: This is a modestly helpful liquidity event, but mostly an execution of the financing plan already in place. It supports the clinical story without changing it—and confirms that TuHURA still needs repeated external funding to advance its programs.
IFx-2.0 preliminary results, first half 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!